TAGRISSO (osimertinib)

TAGRISSO is an EGFR TKI indicated as a monotherapy for:

Second-line TAGRISSO

For patients initiated on a TKI other than osimertinib in the 1L setting, some may be suitable for 2L Tagrisso

The T790M mutation

Most patients who receive first/second-generation EGFR TKIs as 1L treatment progress after 9–14 months.6 In up to 60% of these patients,  the acquired resistance is driven by a T790M mutation.6-8

TAGRISSO selectively targets both EGFRm and EGFR T790M resistance mutations.1

T790M Mutation
T790M Mutation